Evolus PE Ratio 2016-2025 | EOLS
Current and historical p/e ratio for Evolus (EOLS) from 2016 to 2025. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Evolus PE ratio as of January 12, 2026 is 0.00.
| Evolus PE Ratio Historical Data | |||
|---|---|---|---|
| Date | Stock Price | TTM Net EPS | PE Ratio |
| 2026-01-12 | 5.77 | 0.00 | |
| 2025-09-30 | 6.14 | $-0.92 | 0.00 |
| 2025-06-30 | 9.21 | $-0.98 | 0.00 |
| 2025-03-31 | 12.03 | $-0.89 | 0.00 |
| 2024-12-31 | 11.04 | $-0.81 | 0.00 |
| 2024-09-30 | 16.20 | $-0.91 | 0.00 |
| 2024-06-30 | 10.85 | $-0.91 | 0.00 |
| 2024-03-31 | 14.00 | $-1.05 | 0.00 |
| 2023-12-31 | 10.53 | $-1.09 | 0.00 |
| 2023-09-30 | 9.14 | $-1.11 | 0.00 |
| 2023-06-30 | 7.27 | $-1.17 | 0.00 |
| 2023-03-31 | 8.46 | $-1.27 | 0.00 |
| 2022-12-31 | 7.51 | $-1.32 | 0.00 |
| 2022-09-30 | 8.05 | $-1.42 | 0.00 |
| 2022-06-30 | 11.60 | $-1.41 | 0.00 |
| 2022-03-31 | 11.22 | $-1.30 | 0.00 |
| 2021-12-31 | 6.51 | $-0.83 | 0.00 |
| 2021-09-30 | 7.62 | $-3.78 | 0.00 |
| 2021-06-30 | 12.65 | $-3.77 | 0.00 |
| 2021-03-31 | 12.99 | $-4.09 | 0.00 |
| 2020-12-31 | 3.36 | $-4.84 | 0.00 |
| 2020-09-30 | 3.91 | $-2.03 | 0.00 |
| 2020-06-30 | 5.30 | $-2.67 | 0.00 |
| 2020-03-31 | 4.15 | $-3.41 | 0.00 |
| 2019-12-31 | 12.17 | $-3.22 | 0.00 |
| 2019-09-30 | 15.62 | $-3.21 | 0.00 |
| 2019-06-30 | 14.62 | $-2.71 | 0.00 |
| 2019-03-31 | 22.57 | $-2.03 | 0.00 |
| 2018-12-31 | 11.90 | $-1.93 | 0.00 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $0.374B | $0.266B |
| Evolus, Inc. is a medical aesthetics company. It focuses on providing physicians and patients in aesthetic procedures and treatments. The company focuses on the self-pay aesthetic market and its lead product candidate, DWP-450, is an injectable 900 kDa purified botulinum toxin type A complex. Evolus, Inc. is based in Irvine, California. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Abbott Laboratories (ABT) | United States | $216.733B | 24.98 |
| EssilorLuxottica (ESLOY) | France | $149.439B | 0.00 |
| Boston Scientific (BSX) | United States | $141.899B | 32.45 |
| Stryker (SYK) | United States | $138.196B | 27.44 |
| Medtronic (MDT) | Ireland | $124.291B | 17.22 |
| Medline (MDLN) | United States | $56.122B | 0.00 |
| Lonza Group Ag (LZAGY) | Switzerland | $49.743B | 0.00 |
| Agilent Technologies (A) | United States | $41.955B | 26.52 |
| GE HealthCare Technologies (GEHC) | United States | $39.585B | 18.93 |
| ResMed (RMD) | United States | $37.629B | 26.04 |
| Koninklijke Philips (PHG) | Netherlands | $28.695B | 18.74 |
| Terumo (TRUMY) | Japan | $21.868B | 24.62 |
| Insulet (PODD) | United States | $19.595B | 60.82 |
| Zimmer Biomet Holdings (ZBH) | United States | $18.124B | 11.30 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $14.309B | 0.00 |
| Baxter (BAX) | United States | $10.358B | 8.36 |
| Sunny Optical Technology (SNPTF) | China | $9.589B | 0.00 |
| Bio-Rad Laboratories (BIO) | United States | $8.713B | 31.33 |
| Demant (WILYY) | Denmark | $7.372B | 0.00 |
| BillionToOne (BLLN) | United States | $4.538B | 0.00 |
| Lantheus Holdings (LNTH) | United States | $4.475B | 13.63 |
| Haemonetics (HAE) | United States | $3.881B | 17.27 |
| Envista Holdings (NVST) | United States | $3.844B | 22.06 |
| ICU Medical (ICUI) | United States | $3.732B | 23.70 |
| Prestige Consumer Healthcare (PBH) | United States | $3.140B | 14.32 |
| Shandong Weigao Medical Polymer (SHWGF) | China | $3.099B | 0.00 |
| QuidelOrtho (QDEL) | United States | $2.266B | 14.57 |
| Perrigo (PRGO) | Ireland | $2.056B | 5.15 |
| Neogen (NEOG) | United States | $2.038B | 44.62 |
| LeMaitre Vascular (LMAT) | United States | $1.902B | 38.28 |
| AtriCure (ATRC) | United States | $1.871B | 0.00 |
| Curaleaf Holdings (CURLF) | Canada | $1.845B | 0.00 |
| Green Thumb Industries (GTBIF) | United States | $1.819B | 79.73 |
| Phibro Animal Health (PAHC) | United States | $1.614B | 16.13 |
| Lumexa Imaging Holdings (LMRI) | United States | $1.496B | 0.00 |
| AdaptHealth (AHCO) | United States | $1.436B | 20.78 |
| Kestra Medical Technologies (KMTS) | United States | $1.366B | 0.00 |
| BioLife Solutions (BLFS) | United States | $1.157B | 343.43 |
| Capricor Therapeutics (CAPR) | United States | $1.121B | 0.00 |
| Tilray Brands (TLRY) | Canada | $1.044B | 0.00 |
| Maravai LifeSciences Holdings (MRVI) | United States | $1.007B | 0.00 |
| InMode (INMD) | Israel | $0.916B | 10.35 |
| Omeros (OMER) | United States | $0.909B | 0.00 |
| CeriBell (CBLL) | United States | $0.869B | 0.00 |
| Valneva SE (VALN) | France | $0.840B | 0.00 |
| VAREX IMAGING (VREX) | United States | $0.558B | 15.12 |
| Cresco Labs (CRLBF) | United States | $0.497B | 0.00 |
| Verano Holdings (VRNO) | United States | $0.489B | 0.00 |
| Brainsway (BWAY) | Israel | $0.474B | 80.63 |
| Canopy Growth (CGC) | Canada | $0.453B | 0.00 |
| SNDL (SNDL) | Canada | $0.436B | 0.00 |
| Cerus (CERS) | United States | $0.436B | 0.00 |
| Quanterix (QTRX) | United States | $0.344B | 0.00 |
| SEMPERIT AG HLD (SEIGY) | Austria | $0.317B | 0.00 |
| TriSalus Life Sciences (TLSI) | United States | $0.293B | 0.00 |
| Viemed Healthcare (VMD) | United States | $0.278B | 22.12 |
| TerrAscend (TSNDF) | Canada | $0.259B | 0.00 |
| Sanuwave Health (SNWV) | United States | $0.252B | 0.00 |
| Aurora Cannabis (ACB) | Canada | $0.241B | 142.00 |
| High Tide (HITI) | Canada | $0.238B | 0.00 |
| Organigram Global (OGI) | Canada | $0.232B | 0.00 |
| Owens & Minor (OMI) | United States | $0.217B | 2.17 |
| Sanara MedTech (SMTI) | United States | $0.213B | 0.00 |
| Accendra Health (ACH) | United States | $0.207B | 2.08 |
| Vireo Growth (VREOF) | United States | $0.204B | 0.00 |
| OraSure Technologies (OSUR) | United States | $0.193B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.192B | 16.92 |
| Quipt Home Medical (QIPT) | United States | $0.154B | 0.00 |
| Apyx Medical (APYX) | United States | $0.153B | 0.00 |
| FitLife Brands (FTLF) | United States | $0.146B | 0.00 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.137B | 0.00 |
| Exagen (XGN) | United States | $0.135B | 0.00 |
| Jushi Holdings (JUSHF) | United States | $0.120B | 0.00 |
| Fonar (FONR) | United States | $0.115B | 16.75 |
| Biote (BTMD) | United States | $0.115B | 5.02 |
| MacroGenics (MGNX) | United States | $0.113B | 0.00 |
| ImmuCell (ICCC) | United States | $0.060B | 25.65 |
| Sharps Technology (STSS) | United States | $0.059B | 0.00 |
| Nephros (NEPH) | United States | $0.048B | 34.92 |
| Cytosorbents (CTSO) | United States | $0.044B | 0.00 |
| Rockwell Medical (RMTI) | United States | $0.039B | 0.00 |
| Jin Medical (ZJYL) | China | $0.039B | 0.00 |
| Modular Medical (MODD) | United States | $0.037B | 0.00 |
| Veru (VERU) | United States | $0.036B | 0.00 |
| United-Guardian (UG) | United States | $0.029B | 14.47 |
| Allurion Technologies (ALUR) | United States | $0.017B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.016B | 0.00 |
| Bonk (BNKK) | United States | $0.015B | 0.00 |
| INLIF (INLF) | China | $0.009B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.009B | 0.00 |
| Flora Growth (FLGC) | United States | $0.007B | 0.00 |
| IM Cannabis (IMCC) | Canada | $0.007B | 0.00 |
| Zynex (ZYXI) | United States | $0.004B | 0.00 |
| Agape ATP (ATPC) | $0.004B | 0.00 | |
| GlucoTrack (GCTK) | United States | $0.003B | 0.00 |
| Functional Brands (MEHA) | United States | $0.003B | 0.00 |
| Meihua Medical Technologies (MHUA) | China | $0.002B | 0.00 |
| Akanda (AKAN) | Canada | $0.000B | 0.00 |
| InterCure (INCR) | Israel | $0.000B | 0.00 |
| InVivo Therapeutics Holdings (NVIVQ) | United States | $0.000B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.000B | 0.00 |